MISGUIDED PANIC AND MISSED OPPORTUNITY FOR PHARMACEUTICAL INVENTIONS: HOW UNEXPECTED RESULTS ECLIPSED REASONABLE EXPECTATION OF SUCCESS IN BMS V. TEVA.

The article focuses on the decision of the U.S. Court of Appeals for the Federal Circuit in the case Bristol-Myers Squibb Co. v. Teva Pharmaceuticals U.S.A, Inc. regarding the assessment of the reasonable expectation of success of pharmaceutical and chemical inventions. It mentions that the Court held that Bristol-Myers Squibb's patent for Entecavir, a drug used to treat chronic hepatitis B, was invalid and Bristol-Myers and Teva Pharmaceuticals alleging patent infringement.